论文部分内容阅读
目的观察乳杆菌LB散联合传统三联疗法治疗幽门螺杆菌(Hp)感染的疗效及不良反应,探讨Hp治疗新途径。方法选择90例Hp阳性的慢性胃炎、消化性溃疡患者分为对照组(雷贝拉唑、克拉霉素、阿莫西林三联疗法)和治疗组(乳杆菌LB散联用三联疗法),疗程均为2wk。每周调查1次患者的不良反应情况及其耐受程度。治疗结束4wk后复查~(14)C-尿素呼气试验和尿素酶试验,判断根除Hp疗效。结果 Hp的根除率按ITT分析及PP分析,对照组为71%和78%,治疗组为89%和93%(P<0.05);治疗组胃肠道不良反应低于对照组(P<0.05)。结论乳杆菌LB散联合三联疗法是根除Hp的一种有效方法,且能够显著减少三联疗法的胃肠道不良反应。
Objective To observe the efficacy and adverse reactions of Lactobacillus LB powder combined with traditional triple therapy in the treatment of Helicobacter pylori (Hp) infection and explore new ways of Hp therapy. Methods Ninety chronic Hp-positive gastritis patients were selected. Patients with peptic ulcer were divided into control group (rabeprazole, clarithromycin, amoxicillin triple therapy) and treatment group (lactobacillus LB combined triple therapy) For 2wk. A weekly survey of patients with adverse reactions and their tolerance. 4wk after the end of treatment review ~ (14) C-urea breath test and urease test to determine the efficacy of eradication of Hp. Results The eradication rate of Hp was 71% and 78% in the control group and 89% and 93% in the control group (P <0.05) by ITT analysis and PP analysis. The gastrointestinal adverse reactions in the treatment group were lower than those in the control group (P <0.05 ). Conclusion Lactobacillus LB combined with triple therapy is an effective method to eradicate Hp, and can significantly reduce the triple therapy of gastrointestinal adverse reactions.